Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...

Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

The FDA's approval of Alnylam's heart disease drug expands treatment options in a market poised for growth. Meanwhile, the ...

It's reported more than 8 million Americans take a blood thinner. One has been recalled for potential absorption issues.

In summary, rosiglitazone may help control diabetes, but its serious impact on heart health makes it a risky choice. The Yale ...

University of Virginia School of Medicine scientists have created a computational tool to accelerate the development of new ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.